# Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
Canonical URL: https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-presents-soquelitinib-phase-1-atopic-dermatitis-data-at-the-society-for-investigative-dermatology-sid-annual-meeting
Ticker: CRVS
Company: Corvus Pharmaceuticals
Source: Corvus Pharmaceuticals
Published: 2026-05-14 11:00 EST
Original Source URL: https://investor.corvuspharma.com
## Summary

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following

## Article Body
New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following
## Recent Company News
- 2026-05-20 20:01 EST — [Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-conference-and-goldman-sachs-47th-annual-global-healthcare-conference) — Source: Corvus Pharmaceuticals
- 2026-05-14 11:00 EST — [Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-presents-soquelitinib-phase-1-atopic-dermatitis-data-at-the-society-for-investigative-dermatology-sid-annual-meeting) — Source: Corvus Pharmaceuticals
- 2026-05-07 20:01 EST — [Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-first-quarter-2026-financial-results) — Source: Corvus Pharmaceuticals
- 2026-04-23 11:30 EST — [Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors) — Source: Corvus Pharmaceuticals
- 2026-04-21 11:30 EST — [Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-to-host-investor-and-analyst-meeting-on-may-14-2026-to-highlight-soquelitinib-data-being-presented-at-the-society-for-investigative-dermatology-sid-annual-meeting) — Source: Corvus Pharmaceuticals
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)